Steven Burill, to give plenary keynote at Genome-wide Partnering & Deal-making, May 30-31, Boston

Top Quote G. Steven Burill, CEO, Burill &Co. will be giving a plenary keynote presentation entitled "Innovating in the New Austerity: What's Really Happening and Why Creative Dealmaking is Essential" at the Genome-wide Partnering & Deal-making conference (May 30-31, 2012 in Boston, MA). End Quote
  • Boston, MA-NH (1888PressRelease) April 12, 2012 - Pharmaceutical R&D spending is falling, the demand for innovation is increasing, and the traditional business model for the industry is failing. What does innovation look like today in the new austerity and what will it take to be successful? What's required is creativity in raising money, making deals, and forging new business models. Burrill brings his 45 years of successful dealmaking, company building, and investing to this discussion.

    G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves on the Boards of Directors of AliveCor, Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (TSX: NDQ), Proventys, Targacept (NASDAQ: TRGT) and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.

    The Genome-wide Partnering & Deal-making Conference is a forum for pharmaceutical, diagnostics, technology and healthcare companies to discuss investments and partnerships in the genomic field. Topics of discussion are companion diagnostics and partnering for personalized medicine, regulatory and reimbursement issues and the ethical, legal and social implications (ELSI) of human genome sequencing.

    The conference is part of the Omics Evolution Summit, which includes 6 co-located conferences. Register for the entire summit and have access to the all of the following conferences:

    2nd Genomic & Proteomic Drug Discovery Conference
    2nd Epigenetics in Drug Discovery Conference
    7th Protein Kinases in Drug Discovery Conference
    3rd RNAi Research and Development Conference
    2nd Next Generation Sequencing

    Sign up for the pre-summit workshop on Clinical Sequencing on May 29th. This interactive workshop is dedicated to discussing emerging technologies, current and future trends of clinical sequencing, and the implementation of next generation sequencing in a CLIA environment.

    For more information, please visit

  • FB Icon Twitter Icon In-Icon
Contact Information